Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward α1- and α2-adrenoceptors

被引:113
作者
Barbaro, R
Betti, L
Botta, M
Corelli, F
Giannaccini, G
Maccari, L
Manetti, F
Strappaghetti, G
Corsano, S
机构
[1] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[2] Univ Pisa, Dipartimento Psichiat Neurobiol Farmacol & Biotec, I-56126 Pisa, Italy
[3] Univ Perugia, Ist Chim & Tecnol Farmaco, I-06123 Perugia, Italy
关键词
D O I
10.1021/jm010821u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of new pyridazin-3(2H)-one derivatives (3 and 4) were evaluated for their in vitro affinity toward both alpha (1)- and alpha (2)-adrenoceptors by radioligand receptor binding assays. All target compounds showed good affinities for the al-adrenoceptor, with K-i values in the low nanomolar range. The polymethylene chain constituting the spacer between the furoylpiperazinyl pyridazinone and the arylpiperazine moiety was shown to influence the affinity and selectivity of these compounds. Particularly, a gradual increase in affinity was observed by lengthening the polymethylene chain up to a maximum of seven carbon atoms. In addition, compound 3k, characterized by a very interesting alpha (1)-AR affinity (1.9 nM), was also shown to be a highly selective alpha (1)-AR antagonist, the affinity ratio for alpha (2)- and alpha (1)-adrenoceptors being 274. To gain insight into the structural features required for al antagonist activity, the pyridazinone derivatives were submitted to a pharmacophore generation procedure using the program Catalyst. The resulting pharmacophore model showed high correlation and predictive power. It also rationalized the relationships between structural properties and biological data of, and external to, the pyridazinone class.
引用
收藏
页码:2118 / 2132
页数:15
相关论文
共 44 条
[1]  
Allen F.H., 1993, CHEM AUTOMAT NEWS, V8, P31
[2]   ALPHA-1 ADRENOCEPTOR BLOCKADE WITH DOXAZOSIN IN HYPERTENSION - EFFECTS ON BLOOD-PRESSURE AND LIPOPROTEINS [J].
AMES, RP ;
KIYASU, JY .
JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (02) :123-127
[3]  
Bonuso S, 1994, Acta Neurol (Napoli), V16, P1
[4]  
BOURDAIS J, 1968, B SOC CHIM FR, P3246
[5]   Ligand design for α1 adrenoceptor subtype selective antagonists [J].
Bremner, JB ;
Coban, B ;
Griffith, R ;
Groenewoud, KM ;
Yates, BF .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (01) :201-214
[6]   Pharmacophore development for antagonists at alpha(1) adrenergic receptor subtypes [J].
Bremner, JB ;
Coban, B ;
Griffith, R .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1996, 10 (06) :545-557
[7]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[8]  
CAINE M, 1990, UROL CLIN N AM, V17, P641
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   STUDIES ON QUINAZOLINES .5. 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES - A NOVEL CLASS OF POTENT AND SELECTIVE ALPHA(1)-ADRENOCEPTOR ANTAGONISTS AND ANTIHYPERTENSIVE AGENTS [J].
CHERN, JW ;
TAO, PL ;
YEN, MH ;
LU, GY ;
SHIAU, CY ;
LAI, YJ ;
CHIEN, SL ;
CHAN, CH .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (15) :2196-2207